Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how ARIEL3 Was a Phase 3 Trial Looking at Rucaparib Significant improvement in progression-free survival.
ARIEL3 Was a Phase 3 Trial Looking at Rucaparib Significant improvement in progression-free survival
